Cargando…
Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption
PURPOSE: Intestinal ischemia-reperfusion injury (i–IRI) involves a blood flow interruption in an intestinal segment followed by blood flow restoration. When blood flow is restored, oxidative and inflammatory molecules are distributed throughout the bloodstream, triggering both local and systemic dam...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518153/ https://www.ncbi.nlm.nih.gov/pubmed/37750172 http://dx.doi.org/10.2147/JIR.S426396 |
_version_ | 1785109452178849792 |
---|---|
author | Garcia-Alonso, Ignacio Velasco-Oraa, Xabier Cearra, Iñigo Iturrizaga Correcher, Sira Mar Medina, Carmen Alonso-Varona, Ana García Ruiz de Gordejuela, Amador Ruiz-Montesinos, Inmaculada Herrero de la Parte, Borja |
author_facet | Garcia-Alonso, Ignacio Velasco-Oraa, Xabier Cearra, Iñigo Iturrizaga Correcher, Sira Mar Medina, Carmen Alonso-Varona, Ana García Ruiz de Gordejuela, Amador Ruiz-Montesinos, Inmaculada Herrero de la Parte, Borja |
author_sort | Garcia-Alonso, Ignacio |
collection | PubMed |
description | PURPOSE: Intestinal ischemia-reperfusion injury (i–IRI) involves a blood flow interruption in an intestinal segment followed by blood flow restoration. When blood flow is restored, oxidative and inflammatory molecules are distributed throughout the bloodstream, triggering both local and systemic damage. Our goal was to evaluate the potential of three antioxidant and/or anti–inflammatory compounds (curcumin, dexmedetomidine and α-tocopherol) to prevent or reverse local and systemic damage induced by i–IRI. METHODS: i-IRI was induced by placing a microvascular clip in the superior mesenteric artery of female WAG/RijHsd rats; the clip was removed after 1h and reperfusion was allowed for 4h. Curcumin (200 mg/kg, orally), α-tocopherol (20 mg/kg, i.p.), and dexmedetomidine (5 or 20 µg/kg, s.c.; DEX5 and DEX20, respectively) were administered. Blood and terminal ileum specimens were collected for biochemical and histological determination. Furthermore, D-xylose absorption test was performed to evaluate intestinal absorption; after completing the 1-hour ischemia and 4-hour reperfusion period, 1 mL of aqueous D-xylose solution (0.615 mg/mL) was administered orally, and one hour later, plasma D-xylose levels were quantified. RESULTS: The histological injury degree (HID) measured by the Chiu scale was significantly reduced when the treatments were applied (non-treated rats, 2.6 ± 0.75; curcumin, 1.54 ± 0.8; DEX5, 1.47 ± 0.7; DEX20 1.14 ± 0.5; and α-tocopherol, 1.01 ± 0.6); intestinal absorptive capacity also improved in all cases healthy rats (2.06 ± 0.07 µg/mL; non-treated, 1.18 ± 0.07 µg/mL; curcumin 1.76 ± 0.3 µg/mL; DEX5, 2.29 ± 0.2 µg/mL; DEX20, 2.25 ± 0.26 µg/mL; and α-tocopherol 1.66 ± 0.21 µg/mL). However, it failed to reduce liver enzyme levels. Finally, only dexmedetomidine significantly reduced urea and creatinine levels compared to non-treated animals. CONCLUSION: All drugs were effective in reducing HID, although α-tocopherol was effective to a greater extent. Only dexmedetomidine reverted intestinal absorption to normal values of healthy animals. |
format | Online Article Text |
id | pubmed-10518153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105181532023-09-25 Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption Garcia-Alonso, Ignacio Velasco-Oraa, Xabier Cearra, Iñigo Iturrizaga Correcher, Sira Mar Medina, Carmen Alonso-Varona, Ana García Ruiz de Gordejuela, Amador Ruiz-Montesinos, Inmaculada Herrero de la Parte, Borja J Inflamm Res Original Research PURPOSE: Intestinal ischemia-reperfusion injury (i–IRI) involves a blood flow interruption in an intestinal segment followed by blood flow restoration. When blood flow is restored, oxidative and inflammatory molecules are distributed throughout the bloodstream, triggering both local and systemic damage. Our goal was to evaluate the potential of three antioxidant and/or anti–inflammatory compounds (curcumin, dexmedetomidine and α-tocopherol) to prevent or reverse local and systemic damage induced by i–IRI. METHODS: i-IRI was induced by placing a microvascular clip in the superior mesenteric artery of female WAG/RijHsd rats; the clip was removed after 1h and reperfusion was allowed for 4h. Curcumin (200 mg/kg, orally), α-tocopherol (20 mg/kg, i.p.), and dexmedetomidine (5 or 20 µg/kg, s.c.; DEX5 and DEX20, respectively) were administered. Blood and terminal ileum specimens were collected for biochemical and histological determination. Furthermore, D-xylose absorption test was performed to evaluate intestinal absorption; after completing the 1-hour ischemia and 4-hour reperfusion period, 1 mL of aqueous D-xylose solution (0.615 mg/mL) was administered orally, and one hour later, plasma D-xylose levels were quantified. RESULTS: The histological injury degree (HID) measured by the Chiu scale was significantly reduced when the treatments were applied (non-treated rats, 2.6 ± 0.75; curcumin, 1.54 ± 0.8; DEX5, 1.47 ± 0.7; DEX20 1.14 ± 0.5; and α-tocopherol, 1.01 ± 0.6); intestinal absorptive capacity also improved in all cases healthy rats (2.06 ± 0.07 µg/mL; non-treated, 1.18 ± 0.07 µg/mL; curcumin 1.76 ± 0.3 µg/mL; DEX5, 2.29 ± 0.2 µg/mL; DEX20, 2.25 ± 0.26 µg/mL; and α-tocopherol 1.66 ± 0.21 µg/mL). However, it failed to reduce liver enzyme levels. Finally, only dexmedetomidine significantly reduced urea and creatinine levels compared to non-treated animals. CONCLUSION: All drugs were effective in reducing HID, although α-tocopherol was effective to a greater extent. Only dexmedetomidine reverted intestinal absorption to normal values of healthy animals. Dove 2023-09-20 /pmc/articles/PMC10518153/ /pubmed/37750172 http://dx.doi.org/10.2147/JIR.S426396 Text en © 2023 Garcia-Alonso et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Garcia-Alonso, Ignacio Velasco-Oraa, Xabier Cearra, Iñigo Iturrizaga Correcher, Sira Mar Medina, Carmen Alonso-Varona, Ana García Ruiz de Gordejuela, Amador Ruiz-Montesinos, Inmaculada Herrero de la Parte, Borja Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption |
title | Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption |
title_full | Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption |
title_fullStr | Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption |
title_full_unstemmed | Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption |
title_short | Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption |
title_sort | prophylactic treatment of intestinal ischemia-reperfusion injury reduces mucosal damage and improves intestinal absorption |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518153/ https://www.ncbi.nlm.nih.gov/pubmed/37750172 http://dx.doi.org/10.2147/JIR.S426396 |
work_keys_str_mv | AT garciaalonsoignacio prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT velascooraaxabier prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT cearrainigo prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT iturrizagacorrechersira prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT marmedinacarmen prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT alonsovaronaana prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT garciaruizdegordejuelaamador prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT ruizmontesinosinmaculada prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption AT herrerodelaparteborja prophylactictreatmentofintestinalischemiareperfusioninjuryreducesmucosaldamageandimprovesintestinalabsorption |